| Previous close | 19.45 |
| Open | 19.45 |
| Bid | 18.10 |
| Ask | 22.50 |
| Strike | 75.00 |
| Expiry date | 2024-01-19 |
| Day's range | 19.45 - 19.45 |
| Contract range | N/A |
| Volume | |
| Open interest | 105 |
- GlobeNewswire
Sandoz receives positive CHMP opinion for citrate-free high concentration formulation of adalimumab biosimilar
Sandoz is seeking approval of high concentration formulation (HCF) adalimumab for use in all indications of reference medicine Upon approval, HCF formulation will offer patients enhanced yet familiar experience through increased convenience and reduced injection volumeRecommendation further supports expansion of Sandoz biosimilar immunology portfolio in Europe Basel, January 30, 2023 — Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announced that the Committee fo
- Motley Fool
Could This Be Novartis' Next Blockbuster Medicine?
The Swiss drugmaker recently shared promising phase 3 clinical trial results for this rare-disease drug.
- Zacks
Novartis' (NVS) Unit to Acquire Astellas' Rights of Mycamine
Novartis' (NVS) generic unit Sandoz is set to acquire rights to the antifungal product Mycamine from Astellas.
© 2023 Yahoo. All rights reserved.
